MOS
RARE icon

MGO One Seven’s Ultragenyx Pharmaceutical RARE Stock Holding History

MGO One Seven’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,488
Closed -$268K – 743
2022
Q2 		$268K Sell
4,488
-459
-9% -$28.2K 0.04% 494
2022
Q1 		$359K Buy
4,947
+1
+0% +$70 0.04% 459
2021
Q4 		$416K Sell
4,946
-683
-12% -$55.6K 0.04% 411
2021
Q3 		$472K Buy
5,629
+1
+0% +$90 0.06% 354
2021
Q2 		$537K Sell
5,628
-700
-11% -$72.9K 0.08% 317
2021
Q1 		$720K Sell
6,328
-26
-0.4% -$3.54K 0.12% 214
2020
Q4 		$880K Sell
6,354
-320
-5% -$38K 0.18% 143
2020
Q3 		$549K Buy
+6,674
New +$553K 0.13% 211
2018
Q1 		$0 Hold
6
– – ﹤0.01% 1875
2017
Q4 		$0 Buy
+6
New +$294 ﹤0.01% 1809

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MGO One Seven's RARE Position: Q3 2022 in Review

MGO One Seven sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 4,488 shares — an estimated $268K sold.

MGO One Seven first reported a position in RARE in Q4 2017 and held it in 10 quarters. The position peaked at $880K in Q4 2020. 232 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

  • MGO One Seven reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • MGO One Seven sold 4,488 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $268K.
  • MGO One Seven first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and held it in 10 quarters.
  • MGO One Seven's Ultragenyx Pharmaceutical position peaked at $880K in Q4 2020.
  • 232 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on MGO One Seven's 13F filing for Q3 2022, filed 14 Nov 2022.